T1	Participants 455 542	1692 patients who were refractory to or intolerant of their latest chemotherapy regimen
T2	Participants 39 118	previously treated patients with refractory advanced non-small-cell lung cancer
T3	Participants 942 995	1129 patients were assigned gefitinib and 563 placebo
